Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Feb;24(2):72-7.
doi: 10.1016/S1607-551X(08)70100-1.

Elevation of intraocular pressure after intravitreal injection of triamcinolone acetonide in Taiwanese patients

Yo-Chen Chang  1 , Wen-Chuan Wu
Affiliations

Elevation of intraocular pressure after intravitreal injection of triamcinolone acetonide in Taiwanese patients

Yo-Chen Chang et al. Kaohsiung J Med Sci. 2008 Feb.

Abstract

The purpose of this study was to investigate the incidence and timing of elevation in intraocular pressure (IOP) after intravitreal injection of triamcinolone acetonide (IVTA). This was a retrospective observational case series that included 52 eyes from 52 patients. All patients received intravitreal injection with 4 mg of triamcinolone acetonide. Significant IOP elevation was defined as pressure greater than 21 mmHg. There were 26 males and 26 females included in this study. The mean age was 59.4 years. The mean IOP at baseline and postoperative mean highest IOP were 14.6 mmHg and 21.5 mmHg, respectively. There were 19 (36.5%) patients who experienced significant IOP elevation at a mean of 26.0 days after IVTA. IOP was well-controlled by topical antiglaucoma medication in 17 of these 19 patients. IOP elevation after intravitreal injection with 4 mg of triamcinolone acetonide is not a rare finding. This phenomenon usually starts approximately 1 month after IVTA. Patients considering this treatment should be fully informed of this known adverse effect.

PubMed Disclaimer

References

    1. Penfold PL, Gyovy JF, Hunyor AB, et al. Exudative macular degeneration and intravitreal triamcinolone– a pilot study. Aust NZ J Ophthalmol. 1995; 23: 293–298. - PubMed
    1. Young S, Larkin G, Branley M, et al. Safety and efficacy of intravitreal triamcinolone for cystoid macular edema in uveitis. Clin Exp Ophthalmol. 2001; 29: 2–6. - PubMed
    1. Greenberg PB, Martidis A, Roger AH, et al. Intravitreal triamcinolone acetonide for macular edema due to central retinal vein occlusion. Br J Ophthalmol. 2002; 86: 247–248. - PMC - PubMed
    1. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol. 2001; 132: 425–427. - PubMed
    1. Danis RP, Ciulla TA, Pratt LM, et al. Intravitreal triamcinolone acetonide in exudative age‐related macular degeneration. Retina. 2000; 20: 244–250. - PubMed

LinkOut - more resources